Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib monotherapy in trastuzumab-refractory HER2+ metastatic breast cancer
NCT00051103Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2002
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in breast cancer, sponsored by GSK. Primary endpoint: Objective Response Rate. Started Oct 2002; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00051103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051103.